Akeso wins Chinese approval for cancer drug positioned to rival Merck’s Keytruda
Posted:
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient survival — the gold standard outcome of any cancer study.
Based on research completed as part of a multi-year collaboration with Nokia Bell Labs, biomedical engineers at Duke University are developing a solution. Using a custom-built optical coherence tomography (OCT) imaging system together with artificial intelligence (AI) models grounded in…
Rare conditions in the ICU include both formally classified rare diseases and conditions that occur infrequently in critical care settings. These patients often face delayed diagnosis, limited specialist expertise and complex multisystem involvement, all of which contribute to poorer outcomes…
Attendees
Sponsors and Exhibitors
Contact us